跳至主要内容
临床试验/NL-OMON50356
NL-OMON50356已完成4 期

ong-term memory immunity against Bordetella pertussis in children 9 years of age who have been vaccinated with acellular pertussis vaccines: effect of an extra preadolescent acellular booster vaccination - Pertussis Immunization study

RIVM0 个研究点目标入组 80 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 11(—)

入选标准

  • Good general health;
  • 8-9 years of age;
  • Vaccinated with Infanrix-IPV + Hib (GSK) at 2, 3, 4, and 11 months of age and
  • with Infanrix-IPV (GSK) at 4 years of age;
  • Received all other regular vaccines according to the Dutch NIP;
  • Provision of written informed consent by both parents or legal
  • representatives;
  • Adherent to protocol and available during the study period

排除标准

  • Present evidence of serious disease(s) demanding immunosuppressive medical
  • treatment, like corticosteroids, that might interfere with the results of the
  • study. Treatment within the 3 months before the study (chronic infection,
  • clotting disorder, genetic disorder);
  • Serious infection disease or fever (>38.5°C) within 14 days before the
  • vaccination;
  • Antibiotic use within 14 days before vaccination;
  • Any known primary or secondary immunodeficiency;
  • Previous administration of plasma products (including immunoglobulins) within
  • the last 6 months;
  • Vaccination with any other pertussis vaccine than those described in the
  • inclusion criteria (i.e. vaccinated with Pediacel or Triaxis (both from Sanofi
  • Pasteur MSD));
  • Vaccination other than those used in the NIP within a month before
  • vaccination/ venapuncture;
  • (suspected) Presence of allergy against (one of the) components of het
  • In the past an allergic reactions after vaccination;
  • Neurologic condition (like epilepsy).

研究者

发起方
RIVM

相似试验